Breast lump — triple assessment
breast lump · GI / Surgical
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Any discrete breast lump requires triple assessment: clinical examination, imaging (mammography and/or ultrasound) and tissue biopsy, to confidently distinguish benign disease from breast cancer.
Red flags
- Hard, irregular, fixed or tethered lump
- Skin dimpling, peau d'orange or nipple retraction
- Bloody single-duct nipple discharge
- Axillary lymphadenopathy
- Inflammatory skin changes (inflammatory breast cancer)
Assessment
Differential diagnosis
- Breast carcinoma
- Fibroadenoma
- Breast cyst
- Fat necrosis
- Phyllodes tumour
- Duct ectasia / periductal mastitis
- Lipoma
Investigations
- Clinical breast and axillary examination
- Bilateral mammography (typically age >40) and/or breast ultrasound (younger women)
- Core needle biopsy (preferred) or fine-needle aspiration
- Axillary ultrasound +/- node biopsy
- Breast MRI in selected cases (dense breasts, lobular cancer, implants)
- Receptor status (ER/PR/HER2) and grade on biopsy
Management
- Take a full history including risk factors, family history and nipple/skin changes
- Examine both breasts and axillae systematically
- Refer on a suspected-cancer pathway for any suspicious lump or red-flag feature
- Arrange age-appropriate imaging (ultrasound in younger, mammography plus ultrasound in older women)
- Assign imaging a level of suspicion and biopsy indeterminate/suspicious lesions
- Obtain core biopsy for histology and receptor status
- Correlate all three components (concordance); re-investigate if discordant
- Aspirate simple symptomatic cysts; biopsy complex cysts
- Reassure and discharge concordant benign lesions (e.g. simple fibroadenoma/cyst)
- Refer confirmed malignancy to the breast MDT for staging and treatment planning
- Arrange genetic referral if strong family history
- Provide written results and clear safety-netting
Drugs & doses
Local anaesthetic (lidocaine 1%) for biopsy
Analgesia (paracetamol/NSAID) for procedure discomfort
Neoadjuvant/adjuvant systemic therapy for confirmed cancer per oncology
Endocrine therapy (e.g. tamoxifen/aromatase inhibitor) for ER-positive disease
Anti-HER2 therapy (trastuzumab) for HER2-positive disease
Disposition
Refer on a 2-week-wait breast pathway for one-stop triple assessment; benign concordant lesions discharged, confirmed cancers to the breast MDT.
Complications & pitfalls
- Delayed cancer diagnosis from false reassurance
- Biopsy haematoma/infection
- Patient anxiety
- Missed malignancy in discordant results
Exam pearls
- Concordance of all three components is essential — act on the most suspicious result
- A discrete new lump in any woman warrants triple assessment regardless of age
- Ultrasound is first-line imaging in women under ~40; mammography is added in older women
- Inflammatory breast cancer can mimic mastitis — a non-resolving 'infection' needs biopsy
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.